Hanson Kristopher sold $193K of MPLT

Catalyst4, Inc. purchased 4,400,000 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at $11.38 ($50.07M total) on 2026-08-14.

MapLight Therapeutics (MPLT) priced a $150 million PIPE, selling 9.2M shares at $11.38 and 4.0M pre-funded warrants at $11.3799, exercisable at $0.0001 with no expiration. Proceeds will fund CNS drug ML-007C-MA, including VISTA Phase 2 in Alzheimer’s disease psychosis and ZEPHYR-2 Phase 3 in schizophrenia. Closing expected Aug. 14, 2026.

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and

MapLight Therapeutics (Nasdaq: MPLT) said it entered a securities purchase agreement for a private placement (PIPE) raising about US$150 million in gross proceeds, led by new and existing institutional investors. The deal is expected to close Aug. 14, 2026, subject to customary conditions. Latham & Watkins represents the placement agents.

MapLight Therapeutics (MPLT) shares rose about 5% after the company announced a $150 million private placement. It plans to sell about 9.2 million common shares at $11.38 plus pre-funded warrants for up to 3.98 million more. Proceeds will fund ML-007C-MA trials and working capital; closing expected Aug. 14, 2026.

MapLight Therapeutics (NASDAQ:MPLT) shares rose 5.2% after the company announced a $150 million private placement. It will sell 9,197,887 common shares at $11.38 and pre-funded warrants for up to 3,983,168 shares. Proceeds will fund ML-007C-MA trials and working capital; cash was $351.3 million as of June 30, 2026.